Cleared Traditional

K934168 - CEDIA DIGOXIN PLUS ASSAY

K934168 is an FDA 510(k) clearance for CEDIA DIGOXIN PLUS ASSAY, manufactured by Microgenics Corp.. The device is a Class 2 Toxicology device with product code KXT cleared through the Traditional 510(k) pathway after a 124-day FDA review.

K934168 · Microgenics Corp. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1993
Decision
124d
Days
Class 2
Risk

K934168 is an FDA 510(k) clearance for the CEDIA DIGOXIN PLUS ASSAY. Classified as Enzyme Immunoassay, Digoxin (product code KXT), Class II - Special Controls.

Submitted by Microgenics Corp. (Concord, US). The FDA issued a Cleared decision on December 29, 1993 after a review of 124 days - within the typical 510(k) review window.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3320 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Toxicology review framework, consistent with the majority of Class II 510(k) submissions.

View all Microgenics Corp. devices

FDA 510(k) Submission Details - K934168

510(k) Number K934168 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 27, 1993
Decision Date December 29, 1993
Days to Decision 124 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
37d slower than avg
Panel avg: 87d · This submission: 124d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

KXT Device Classification - Class 2, Special Controls

Product Code KXT Enzyme Immunoassay, Digoxin
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3320
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - KXT Enzyme Immunoassay, Digoxin

All 78
Devices cleared under the same product code (KXT) and FDA review panel - the closest regulatory comparables to K934168.
CEDIA DIGOXIN PLUS ASSAY
K941255 · Microgenics Corp. · Jun 1994
ACE CLINICAL CHEMISTRY SYSTEM
K940267 · Schiapparelli Biosystems, Inc. · May 1994
EMIT 2000 DIGOXIN ASSAY/CALIBRATORS MODIFICATION
K934135 · Syva Co. · Apr 1994
ACA(R) DIGOXIN ANALYTICAL TEST PACK (DGN)
K932732 · Dupont Medical Products · Nov 1993
VIDAS DIGOXIN (DIG)
K932250 · Biomerieux Vitek, Inc. · Sep 1993
DIGOXIN TEST SYSTEM, KXT TX
K931123 · Syva Co. · Aug 1993